We streamline the path discoveries take into the clinic with efficient development practices, while focusing our education on improving quality, safety, and seamless teamwork.
Our Annual Report
Our annual report features Houston Methodist’s latest metrics, research milestones, innovative leaders and strategic collaborative partnerships. Explore our most recent report.
View our Annual Report ➝
View our Annual Report ➝
Facts & Stats
Houston Methodist
- 9 hospitals
- 2.65 million patient encounters
- 152,000 admissions
- 35,400 employees
- 5,500 affiliated physicians
- 876 faculty
- $380 million research & education expenditures
- 2,720 credentialed researchers
- 45,300 learners
Research Funding
- $305 million in annual research expenditures
- $74.9 million in annual education expenditures
- $120 million in total extramural funding
- $51 million in National Institutes of Health funding
- $31 million Translational Research Initiative product development fund
Academic Affiliations & People
- 876 faculty
- 2,720 credentialed researchers
- Affiliated with Weill Cornell Medical School
Research
- 191 licensable technologies
- 16 products in the pipeline
- 1,940 clinical protocols
- 761 active clinical trials
- 212 investigator initiated trials
- 1,990 peer-reviewed publications
- 109 collaborating countries
- 11,300 global collaborations
- Interdisciplinary Departments: Anesthesiology and Critical Care; Cardiology; Cardiovascular Sciences; Cardiovascular Surgery; Charles W. Duncan Jr. Department of Medicine; Stanley H. Appel Department of Neurology; Neurosurgery; Obstetrics and Gynecology; Ophthalmology; Oral and Maxillofacial Surgery; Orthopedic Surgery; Otolaryngology; Pathology and Genomic Medicine; Psychiatry and Behavioral Health; Radiation Oncology; Radiology; Surgery; Urology
- Interdisciplinary Centers: Alzheimer’s Disease; Bioenergetics; BioNanoengineering; Blanton Eye Institute; Bookout Center; Brain and Pituitary Treatment; Cardiovascular Regeneration; Critical Care; Digital Health Institute; Health and Nature; Human Performance; Immunobiology and Transplant Science; Infectious Diseases; Liver Disease and Transplantation; Neural Systems Restoration; Neuroregeneration; Orbital Sciences, Medicine, Innovation and Care; Rapid Device Translation; RNA Therapeutics; Safety, Quality and Well-Being Institute
Education
- EnMed: MD and MEng Dual Degree Program with Texas A&M University
- Master in Clinical Translational Management with University of St. Thomas
- 88 GME programs; 477 residents & fellows
- 45,300 total learners
- 917 graduate students & post-docs
- 2 NIH T32 Training Grant Programs
- 2 PhD Programs with Weill Cornell Graduate School of Medical Sciences
Consortia & Collaborative Centers
- Center for Human Performance, collaboration with Rice University
-
Center for Cell and Gene Therapy, collaboration with Baylor College of Medicine and Texas Children’s Hospital
-
Center for Health and Nature, collaboration with Texas A&M University
-
Center for Rapid Device Translation, collaboration with J&J Innovation Labs
-
Digital Health Institute, collaboration with Rice University
-
Gulf Coast Consortium
-
Siemens Imaging Consortium, based at Houston Methodist with six local universities and medical centers
Translational Technologies
- Translational Imaging
- Imaging innovation hub: A Siemens and Houston Methodist-led consortium with Rice University, Texas A&M, UT Health Science Center at Houston, UT Medical Branch at Galveston, University of Houston, and Baylor College of Medicine.
- 7 Tesla MRI and MAGNETOM Terra, allowing for unprecedented visualization of anatomical details, physiology and biological function.
- Cyclotron and nine ventilated hot cells (chemistry labs in lead boxes) to produce clinical- grade and rare custom radiopharmaceuticals for advanced diagnostic and therapeutic imaging.
- Inveon dedicated PET system, Inveon multimodality SPECT/CT system, Caliper IVIS-200 system, and Maestro in vivo fluorescence imaging system.
- Translational Production & Quality and Clinical Trial Support
- Good Laboratory Practice (GLP) facilities perform risk, safety and efficacy assessment studies in compliance with FDA guidelines for preclinical proof-of-concept testing.
- Ann Kimball and John W. Johnson Center for Cellular Therapeutics to translate laboratory discoveries into cutting-edge cellular therapies for patient care.
- Center for RNA Therapeutics provides access to state-of-the-art RNA facilities for manufacturing and technology.
- Current Good Manufacturing Practices (cGMP) facilities to produce pharmaceuticals, vaccines and nanoparticles for testing and research.
- Cockrell Center for Advanced Therapeutics and Clinical Research Phase I Unit supports first-in-human and proof-of-concept clinical trials.
- Good Laboratory Practice (GLP) facilities perform risk, safety and efficacy assessment studies in compliance with FDA guidelines for preclinical proof-of-concept testing.
- Core Facilities for Technology, Data Analysis, and Services Access
- Advanced Cellular and Tissue Microscopy, Ann Kimball and John W. Johnson Center for Cellular Therapeutics; Biorepository; Center for Health Data Science and Analytics; Clinical Research Services; Comparative Medicine; Flow Cytometry; Machine Shop; Microscopy Core (AFM) & X-ray Irradiators; Preclinical Catheterization Laboratory; Research Pathology; Translational Imaging Center; Translational Production & Quality
- Advanced Cellular and Tissue Microscopy, Ann Kimball and John W. Johnson Center for Cellular Therapeutics; Biorepository; Center for Health Data Science and Analytics; Clinical Research Services; Comparative Medicine; Flow Cytometry; Machine Shop; Microscopy Core (AFM) & X-ray Irradiators; Preclinical Catheterization Laboratory; Research Pathology; Translational Imaging Center; Translational Production & Quality
Our Research Philosophy
Houston Methodist clinicians and investigators all have the same goal, to build research teams that bridge the boundaries between specialties, innovate in health care technology and train current and future clinicians and researchers from around the world in translational medicine and advanced technology. We want to improve global health by streamlining the path discoveries take into the clinic with inventive development practices.
Because most innovation occurs at the intersection of disciplines rather than within a silo, we have structured the research enterprise in a way that allows us to create interdisciplinary points of connection by providing platform technology support to clinical research programs throughout Houston Methodist. This intentional blending of departmental boundaries adds a new level of innovative, collaborative research, conducted by teams of scientists from a variety of disciplines and backgrounds.
The various medical disciplines intersect at one or all of three broad strategic areas — precision medicine, biotherapeutics and restorative medicine and outcomes, quality and health care performance.
Because most innovation occurs at the intersection of disciplines rather than within a silo, we have structured the research enterprise in a way that allows us to create interdisciplinary points of connection by providing platform technology support to clinical research programs throughout Houston Methodist. This intentional blending of departmental boundaries adds a new level of innovative, collaborative research, conducted by teams of scientists from a variety of disciplines and backgrounds.
The various medical disciplines intersect at one or all of three broad strategic areas — precision medicine, biotherapeutics and restorative medicine and outcomes, quality and health care performance.
Precision medicine
Precision medicine is a model in which health care — decisions, practices and products — is customized for the individual characteristics of each patient. Houston Methodist defines precision medicine, beyond the well-established ‘molecular signature’ from genetic and proteomic characteristics of a patient, to inclusion of anatomical and temporal information from imaging to provide a more a comprehensive understanding of a patient’s ‘health signature’ at a given encounter. We also take the next step in using this health signature to tailor the efficiency and precision of a treatment regimen for the patient to achieve the best outcome.
Biotherapeutics and Restorative Medicine
Biotherapeutics & restorative medicine - Definitions for restorative medicine tend to focus primarily on stem cell biology and engineering. At Houston Methodist, we take a biotherapeutics approach to restorative medicine by developing medical products for modulation of stem cell plasticity and differentiation, modulators of immune-based degenerative and restorative processes and engineered biomaterials to support restoration. These restorative solutions are addressing challenges in heart tissue restoration, transplant organ preservation and protection and restoration of bone and joint function.
Outcomes, Quality and Health Care Performance
Outcomes, quality and health care performance uses interdisciplinary research to improve outcomes for patients in acute care settings. By improving clinical practice, supporting patient decision-making, evaluating innovative therapeutic procedures and promoting education for health professionals, we ensure that our research discoveries provide the most efficient and effective regimens and practice in clinical settings. Houston Methodist is particularly well positioned to tackle the clinical challenge of delivering high-quality, cost-effective care, as an organization with a broad network of private and employed physicians with notably diverse patient populations.